Study of LCF Chemotherapy in Unknown Primary Cancer
Author Information
Author(s): A Rigg, D Cunningham, M Gore, M Hill, M O'Brien, M Nicolson, J Chang, M Watson, A Norman, A Hill, J Oates, H Moore, P Ross
Primary Institution: The Royal Marsden Hospital, Institute of Cancer Research
Hypothesis
The study aims to determine the maximum tolerated dose of 5-FU in combination with leucovorin and carboplatin for patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
Conclusion
The study found that the maximum tolerated dose of 5-FU in the LCF regimen was 370 mg/m², with an overall objective response rate of 25%.
Supporting Evidence
- The maximum tolerated dose of 5-FU was determined to be 370 mg/m².
- 25% of patients had an objective response, including one complete response and nine partial responses.
- The median survival for all patients was 7.8 months.
- Patients reported symptomatic improvements with the LCF regimen.
Takeaway
Doctors tested a new cancer treatment on 40 patients and found that it helped some of them feel better and live longer.
Methodology
The study involved 40 patients with metastatic carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas, treated with a regimen of leucovorin, carboplatin, and 5-FU, with dose escalation based on toxicity.
Limitations
The study had a small sample size and included patients with varying performance statuses.
Participant Demographics
{"median_age":59,"age_range":"31-74","sex_distribution":{"male":23,"female":17}}
Want to read the original?
Access the complete publication on the publisher's website